CyGenica Receives Orphan Drug Designation for Glioblastoma Multiforme (GBM) Treatment

Glioblastoma multiforme (GBM) is a formidable disease, comprising 17% of adult intracranial neoplasms. No identified risk factors are associated with GBM, except for exposure to ionizing radiation. GBM is one of the most aggressive forms of cancer in humans. Despite advancements in surgical techniques and additional treatments, the average survival time remains approximately 1 year. In adults, GBM is the most prevalent type of astrocytoma and is typically associated with a grim prognosis, with a median survival of about 12 months. However, it is rare in children. Around 65% of GBM cases primarily manifest in the cerebral hemispheres, which govern higher cognitive functions such as speech, movement, thought, and sensation. GBMs can also arise in other regions of the brain that regulate sensory perception, temperature sensitivity, balance, and motor function. The most prevalent symptoms of GBM include morning headaches, lethargy, and seizures that vary depending on the type and location of the tumor. Compression of neighboring brain structures due to the tumor’s position can result in motor dysfunction, hormonal irregularities, or changes in behavior and cognitive processes. GBMs are typically diagnosed between the ages of 5 and 9, affecting both boys and girls equally. However, they occur more frequently in children with specific genetic syndromes, including neurofibromatosis 1, Li-Fraumeni syndrome, hereditary nonpolyposis colon cancer, and tuberous sclerosis. The majority of GBM cases, however, have an unknown cause. Treatment options for GBM may encompass neurosurgery, radiation therapy, and chemotherapy.

• Glioblastoma multiforme is the most aggressive malignant primary brain tumor, with an incidence of 2–3 per 100,000 people in the United States and Europe. In children, accounting for only 3% of childhood brain tumors.

However, the current Glioblastoma Multiforme (GBM) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (DSP-7888, Temozolomide, ASC40, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Glioblastoma Multiforme treatment. The key companies in the advanced development stage are Sumitomo Pharma Oncology, Inc., AbbVie, Ascletis Pharmaceuticals Co., Ltd., etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Glioblastoma Multiforme (GBM) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2022 to 2032.